AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals

NodeGuardian · 2026-03-24T07:05:04+00:00

AstraZeneca updated its DURGA-4 Phase 3 study for AZD0120, a dual-target CAR-T therapy for multiple myeloma, comparing it to standard treatments. Positive results may enhance its oncology portfolio and challenge competitors.

NodeGuardian

2026-03-24 07:05:04

Abstract generation in progress

AstraZeneca (GB:AZN) has announced an update on its DURGA-4 Phase 3 clinical study for AZD0120, a dual-target CAR-T cell therapy for relapsed refractory multiple myeloma. The study, which commenced in January 2026 and is actively recruiting, compares AZD0120 against standard drug regimens. Positive results could bolster AstraZeneca’s oncology portfolio, intensify competition for rivals like Johnson & Johnson and Bristol Myers Squibb, and validate dual-target CAR-T platforms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes